



Express Mail Label No.: EV426288625US  
Deposit Date: April 23, 2007

Atty Docket: 94919-010100

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Jean-Francois Savouret  
Serial No.: 10/700,383  
Date Filed: November 4, 2003  
Invention: Stilbene Derivatives and Their Use as Aryl Hydrocarbon Receptor Antagonistic Ligands

Confirmation No.: 5818  
Art Unit: 1621  
Examiner: Rosalynd Keys

\*\*\*\*\*  
**CERTIFICATE OF EXPRESS MAILING (37 C.F.R. § 1.8)**

I hereby certify that this correspondence is being deposited on the date stated below, with the United States Postal Service as Express Mail Label No. EV426288625US, and is addressed to Mail Stop: Amendment, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, on April 23, 2007.

Ben Joplin  
Ben Joplin

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**AMENDMENT**

Sir:

This Amendment is being filed in response to the Office Action mailed from the U.S. Patent and Trademark Office on January 5, 2007 in the above-identified application. Reconsideration and further examination are requested.

A one month extension of time to respond to the Office Action is respectfully requested. A Petition for A One Month Extension of Time and the appropriate fee are being filed concurrently with this Amendment.

**Amendments to the Claims** are shown in the "Listing of the Claims" which begins on page 2 of this paper.

**Remarks** begin on page 8 of this paper.

Please enter the following amendments and remarks.

Listing of Claims

This listing of claims will replace all prior versions and listings of claims in the subject application.

1. (Canceled)

2. (Canceled)

3. (Canceled)

4. (Canceled)

5. (Canceled)

6. (Canceled)

7. (Canceled)

8. (Canceled)

9. (Withdrawn) The use of the stilbene derivatives according to claim 7 as antagonists of AhR ligands to treat pathologies including AhR ligands, by administering to a patient a therapeutically effective amount of the stilbene derivative in need of such treatment.

10. (Canceled)

11. (Previously Presented) The pharmaceutical compositions of claim 32 in a form for administration by the oral, nasal, parenteral or topical route.

12. (Original) The pharmaceutical compositions of claim 11, wherein said form is a gel, capsules, drops, syrup or alcohol syrup, for administration by the oral route, spray or drops for administration by the nasal route, solution for administration by the parenteral route, and cream, ointment, shampoo or lotion for application by the topical route, the vehicle comprising an oil or a pharmaceutically acceptable alcohol.

13. (Previously Presented) The pharmaceutical compositions of claim 32, comprising 0.1 mg to 5 g per dosage unit.

14. (Withdrawn) The use of a pharmaceutical composition of claim 10, for the treatment of conditions selected from dermatitis, acne, psoriasis, hyperkeratotic lesions, eczema, or skin aging and wrinkling associated with common environmental exposure to AhR ligands, by administering to a patient a therapeutically effective amount of said pharmaceutical composition to a patient in need of such treatment.

15. (Withdrawn) The use of pharmaceutical compositions of claim 13 for preventing or avoiding the development of cold or flu symptoms related to viral infections aggravated by AhR ligands, by administering to a patient a therapeutically effective amount of said pharmaceutical composition.

16. (Withdrawn) The use of a pharmaceutical composition of claim 10 for the prevention of AhR ligand-induced triggering of HIV (and other viruses) gene expression and progression of AIDS in a patient, particularly for the treatment of viral infections such as HIV-induced AIDS, by administering to a patient a therapeutically effective amount of said pharmaceutical composition.

17. (Withdrawn) The use of a pharmaceutical composition of claim 10, for the prevention of prion-induced Spongiformis Encephalitis in a human and livestock, by administering to said human or livestock a therapeutically effective amount of said pharmaceutical composition.

18. (Withdrawn) The use of a pharmaceutical composition as claimed in claim 10, for the